Aim: The incidence of melanoma in situ varies throughout the world. It is associated with excellent outcomes, however many of those untreated will go on to develop invasive melanoma with a worse prognosis. There is no previously published data on melanoma in situ (MIS) in New Zealand. Further information is needed to enable better understanding of the disease spectrum.
Methods: De-identified data were obtained from the New Zealand Cancer Registry (NZCR) by way of computerised search for MIS diagnosis. A separate search was performed to identify all patients with invasive melanoma. World Health Organization standard population was used for calculating age standardised rates.
Results: There was a trend to increasing cases of MIS, but a relative plateauing of invasive melanoma. The number of cases for MIS overtook invasive melanoma in 2012. Overall, men had a significantly higher incidence compared to women. Incidence rates varied markedly between different regions of the country.
Conclusions: This paper provides new information about the epidemiology of MIS in New Zealand and its relevance to clinical practice. Public education strategies may be beginning to show effect with the goal of increasing prevention and earlier detection and treatment to enable decrease in melanoma mortality.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Silencing of O-GlcNAc transferase attenuated O-GlcNAcylation and metastatic potentials of melanoma cells through suppression of Akt-NFkB signaling pathway.
Chembiochem
January 2025
Khon Kaen University, Biochemistry, Medicine, 123 Moo 16, 40002, Khon Kaen, THAILAND.
O-GlcNAcylation is an important biological process in regulating the function of many nucleocytoplasmic proteins in cells. Enhancement of O-GlcNAcylation was associated with cancer development and progression. Here, we demonstrated the involvement of O-GlcNAcylation in melanoma metastasis.
View Article and Find Full Text PDFInvestigating orbital foreign device-associated malignancies: a scoping review.
BMC Cancer
January 2025
Department of Plastic Surgery, University of California, Irvine, CA, USA.
Background: While prosthesis-associated malignancies have been acknowledged, awareness among surgeons and patients in the ophthalmologic field remains limited, despite the frequent occurrence of prosthesis-related surgeries. We aim to address this gap through a scoping review of malignancies following ophthalmologic surgeries involving various foreign device/prosthesis/implants.
Methods: Following PRISMA guidelines, we conducted a review using PubMed and Embase for studies on cancer and ophthalmic prostheses/implants.
Risk of second primary malignancies among survivors of cutaneous melanoma: A nationwide population-based study in the Republic of Korea.
Sci Rep
January 2025
Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
There is limited data on the risk of second primary malignancies (SPMs) in Asian melanoma survivors. This study aimed to identify the risk of SPMs in Asian melanoma survivors. Standardized incidence ratios (SIRs) were calculated for overall and specific SPMs.
View Article and Find Full Text PDFSurgical treatment of keratinocyte carcinoma in Danish hospitals 2007-2021: Time trends and impact of patient and tumor characteristics on treatment choices.
J Plast Reconstr Aesthet Surg
January 2025
Department of Plastic Surgery, Odense University Hospital, Denmark.
The incidence of keratinocyte carcinoma (KC) is rising globally, significantly burdening healthcare resources. Treatment options include medical treatment, non-invasive procedures, and surgery, each associated with their distinct benefits and risks. With advanced treatment, the procedures become increasingly invasive for the patients and expensive for the society.
View Article and Find Full Text PDFTargeted intra-tumoral hyperthermia using uniquely biocompatible gold nanorods induces strong immunogenic cell death in two immunogenically 'cold' tumor models.
Front Immunol
January 2025
Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
Introduction: Hyperthermia is an established adjunct in multimodal cancer treatments, with mechanisms including cell death, immune modulation, and vascular changes. Traditional hyperthermia applications are resource-intensive and often associated with patient morbidity, limiting their clinical accessibility. Gold nanorods (GNRs) offer a precise, minimally invasive alternative by leveraging near-infrared (NIR) light to deliver targeted hyperthermia therapy (THT).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!